Insulin Aspart (Novomix 30 Flexpen 100IU/ml) is a fast-acting form of the hormone insulin, prescribed for diabetes mellitus. It is used with other medium- or long-acting insulin products injected just ...

A small number of batches of the insulin medication NovoMix 30 FlexPen and Penfill (Novo Nordisk) are to be recalled in the European Union, and the European Medicines Agency (EMA) is recommending that ...

The European Medicines Agency (EMA) is giving recommendations on how to deal with a recall of some batches of the diabetes medicine NovoMix 30 FlexPen and Penfill. The affected batches are being ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor, diabetes education nurse, or pharmacist. Do not use if you have ever had an allergic ...

According to the medicines watchdog, some batches of the NovoMix 30 Flexpen 100U/ml pre-filled pen and the Novomix 30 Penfill 100U/ml cartridge are being recalled due to a manufacturing problem during ...

Insulin Aspart (Novomix-30 Penfill) is a fast-acting form of the hormone insulin, prescribed for diabetes mellitus. It is used with other medium- or long-acting insulin products injected just below ...

China's biggest solar firms shed nearly one-third of their workforces last year, company filings show, as one of the industries hand-picked by Beijing to drive economic growth grapples with falling ...

One of the affected products is a NovoMix 30 Flexpen The medicines watchdog, the MHRA, is urging people with diabetes to check their insulin pens. It says a manufacturing fault has led to some batches ...

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Insulin Aspart: Key Patent, SPC, and Data Exclusivity Expiry - 44 Country Coverage" report to their offering. Pipeline ...

New Delhi: Novo Nordisk India (www.novonordisk.com), the market leader in diabetes care and the insulin major, today launched two insulin analogues — NovoMix 30 and NovoRapid. NovoMix 30 is premixed ...

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Insulin Aspart - Comprehensive Patent Search" report to their offering. Eliminate unnecessary risk with the industry ...